Estrogen compositions for vaginal administration

• US 20070004693A1
• Filed: 06/16/2006
• Published: 01/04/2007
• Est. Priority Date: 06/16/2005
• Status: Abandoned Application

• Current Assignee: Warner Chilcott Company LLC (Abbvie Incorporated)
• Original Assignee: Warner Chilcott Company Incorporated (Abbvie Incorporated)
• Inventors: Woolfson, David, Gilligan, Claire
• Application Number:
  US11/454,473
• Publication Number:
  US 20070004693A1
• Time in Patent Office: Days
• US Class Current: 514/182
• CPC Class Codes: A61K 31/56 Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 47/38 Cellulose; Derivatives thereof
• CPC Class Codes: A61K 9/0034 Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
• CPC Class Codes: A61P 5/30 Oestrogens

Abstract

Pharmaceutical gel compositions containing estrogen for vaginal administration, as well as a method of making the same, are disclosed.

Claims

1. A pharmaceutical gel composition containing estrogen for vaginal administration comprising:

(a) at least one estrogen in an amount of about 0.00028% to about 1% by weight of the composition;

(b) at least one gelation polymer; and

(c) at least one aqueous solvent;

wherein a portion of the estrogen in the composition is in suspension at 15°

C.

2. The pharmaceutical gel composition of claim 1, wherein the at least one estrogen is selected from the group consisting of 17β

-estradiol, mestranol, conjugated estrogens USP, estrone, and ethinyl estradiol, and salts, esters, and prodrugs thereof.

3. The pharmaceutical gel composition of claim 1, wherein the amount of the at least one estrogen is from about 0.0007% to about 0.05% by weight of the composition.

4. The pharmaceutical gel composition of claim 1, wherein the at least one gelation polymer is selected from the group consisting of cellulose derivatives, gums, and neutralised homopolymers, copolymers and interpolymers having pendent carboxylic acid groups, or their esters, and/or having pendent anhydrides of dicarboxylic acid groups.

5. The pharmaceutical gel composition of claim 1, wherein the at least one gelation polymer is present in an amount sufficient to form a gel with a viscosity of between about 50 and about 1000 Pa·

s at 20°

C.

6. The pharmaceutical gel composition of claim 1, wherein the aqueous solvent is water.

10. The pharmaceutical gel composition of claim 1, wherein the composition is substantially free of estrogen solubilizing agents.

11. The pharmaceutical gel composition of claim 1, further comprising at least one pharmaceutically acceptable excipient.

12. The pharmaceutical gel composition of claim 1, further comprising at least one active ingredient selected from the group consisting of progestogens and androgens.

13. The pharmaceutical gel composition of claim 12, wherein the progestogen is selected from the group consisting of progestogen, 17-hydroxy progestogen esters, 19-nor-17-hydroxy progestogen esters, norgestrel, norgestimate, desogestrel, demegestone, drospirenone, dydrogesterone, medrogestone, medroxy progesterone, medroxyprogesterone acetate, norethesterone, norethindrone, norethindrone acetate, levonorgestrel, 3-ketodesogestrel, gestodene and combinations thereof.

14. The pharmaceutical gel composition of claim 12, wherein the androgen is selected from the group consisting of testosterone, esters thereof, methyl-testosterone, prodrugs thereof and combinations thereof.

18. A method of vaginal administration of estrogen for a female comprising the step of administering the pharmaceutical gel composition of claim 1 to the vaginal epithelial tissue of the female.

7. The pharmaceutical gel composition of claim I, wherein at least 50% of the estrogen in the composition is in suspension at 15°

C.

8. The pharmaceutical gel composition of claim 7, wherein at least 60% of the estrogen in the composition is in suspension at 15°

C.

9. The pharmaceutical gel composition of claim 8, wherein at least 90% of the estrogen in the composition is in suspension at 15°

C.

15. A method of making a pharmaceutical gel composition for vaginal application comprising the step of admixing at least one estrogen in an amount of about 0.00028% to about 1% by weight of the composition with at least one aqueous solvent and at least one gelation polymer to form the pharmaceutical gel composition, wherein a portion of the estrogen in the composition is in suspension at 15°

C.

16. The method of claim 15, wherein the admixing step comprises (a) mixing the at least one estrogen with the at least one aqueous solvent to form an estrogen suspension and (b) combining the estrogen suspension with the at least one gelation polymer to form the pharmaceutical gel composition.

17. A pharmaceutical gel composition made according to the method of claim 15.